Interestingly, checkpoint blockade therapy also induces an expansion of antigen-specific PD-1Neg tumor-infiltrating CD8+ T cells, which can contribute to the therapeutic effect.38 Thus, the combination of Tim-3 and PD-1 blockade resulted in changes in the transcriptional profile of PD-1Neg tumor-infiltrating CD8+ T cells. The gene discussed is HAVCR2; the disease is neoplasm.